Evidence map›Paper›PMID 34099463›Full record

ArticleBMJ open gastroenterology2021

Feasibility and efficacy of a multicomponent exercise medicine programme in patients with pancreatic cancer undergoing neoadjuvant therapy (the EXPAN trial): study protocol of a dual-centre, two-armed phase I randomised controlled trial.

Hao Luo, Daniel A Galvão, Robert U Newton, Colin Tang, Andrew Dean, Kevin Jasas, Mikael Johansson, Ian Yusoff, Nigel Spry, Dennis R Taaffe

Open access · goldAbstract readClinical Trial Protocol
PubMed Full text at PMC Publisher
In one paragraph

Article in BMJ open gastroenterology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.4field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 7 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. A review of physical activity in pancreatic ductal adenocarcinoma: Epidemiology, intervention, animal models, and clinical trials.Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.] · 2022
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Hao LuoExercise Medicine Research Institute, Edith Cowan University, Joondalup, Western Australia, Australia hluo1@our.ecu.edu.au.ORCID 0000-0001-5181-7529
Daniel A GalvãoExercise Medicine Research Institute, Edith Cowan University, Joondalup, Western Australia, Australia.
Robert U NewtonExercise Medicine Research Institute, Edith Cowan University, Joondalup, Western Australia, Australia.
Colin TangExercise Medicine Research Institute, Edith Cowan University, Joondalup, Western Australia, Australia.
Andrew DeanDepartment of Oncology, St John of God Subiaco Hospital, Subiaco, Western Australia, Australia.
Kevin JasasDepartment of Medical Oncology, Sir Charles Gairdner Hospital, Nedlands, Western Australia, Australia.
Mikael JohanssonDepartment of General Surgery, Sir Charles Gairdner Hospital, Nedlands, Western Australia, Australia.
Ian YusoffDepartment of Gastroenterology, Sir Charles Gairdner Hospital, Nedlands, Western Australia, Australia.
Nigel SpryExercise Medicine Research Institute, Edith Cowan University, Joondalup, Western Australia, Australia.
Dennis R TaaffeExercise Medicine Research Institute, Edith Cowan University, Joondalup, Western Australia, Australia.
Edith Cowan University · AUSir Charles Gairdner Hospital · AUSt John of God Subiaco Hospital · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionExercise is emerging as a therapy in oncology for its physical and psychosocial benefits and potential effects on chemotherapy tolerability and efficacy. However, evidence from randomised controlled trials (RCTs) supporting exercise in patients with borderline resectable or locally advanced pancreatic cancer (PanCa) undergoing neoadjuvant therapy (NAT) are lacking. METHODS AND ANALYSIS: The EXPAN trial is a dual-centre, two-armed, phase I RCT. Forty patients with borderline resectable or locally advanced PanCa undergoing NAT will be randomised equally to an exercise intervention group (individualised exercise+standard NAT) or a usual care control group (standard NAT). The exercise intervention will be supervised and consist of moderate to vigorous intensity resistance and aerobic-based training undertaken two times a week for 45-60 min per session for a maximum period of 6 months. The primary outcome is feasibility. Secondary outcomes are patient-related and treatment-related endpoints, objectively measured physical function, body composition, psychological health and quality of life. Assessments will be conducted at baseline, prior to potential alteration of treatment (~4 months postbaseline), at completion of the intervention (maximum 6 months postbaseline) and 3-month and 6-month postintervention (maximum 9 and 12 months postbaseline). ETHICS AND DISSEMINATION: The EXPAN trial has been approved by Edith Cowan University (reference no.: 2020-02011-LUO), Sir Charles Gairdner Hospital (reference no.: RGS 03956) and St John of God Subiaco Hospital (reference no.: 1726). The study results will be presented at national/international conferences and submitted for publications in peer-reviewed journals. TRIAL REGISTRATION NUMBER: ACTRN12620001081909.

Indexed as

Neoadjuvant TherapyPancreatic NeoplasmsExerciseExercise TherapyFeasibility StudiesHumansRandomized Controlled Trials as Topicalternative medicinechemotherapypancreatic cancerquality of lifesurgical resection

Identifiers

PMID34099463
PMCPMC8186755
OpenAlexW3169550624

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.